Our Portfolio Companies' Press Releases
Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company’s Neuro-Oncology Medical Advisory Board
Walnut Creek, CA, USA, March 21, 2022 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately-held oncology company focused on tough–to–treat cancers, is honored
Dr. Gerard Blobe, MD, PhD Joins Vivacitas Oncology’s Solid Tumor Medical Advisory Board
Walnut Creek, CA, USA, March 7th, 2022 – Vivacitas Oncology, Inc., a privately-held oncology company focused on tough–to–treat cancers, proudly announces that Dr. Gerard Blobe,
Vivacitas Oncology to Present at the 2022 BIO CEO & Investor Conference
Walnut Creek, CA, USA, February 14th, 2022 – Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough–to–treat cancers, will present at the upcoming 2022
Dr. Volker W. Stieber, MD, Joins Vivacitas’ Neuro-Oncology Advisory Board
Walnut Creek, CA, USA, February 7, 2022 – Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough–to–treat cancers, is proud to present Dr. Volker
Vivacitas Oncology Strengthens its Neuro-Oncology Board with World-Class Advisor Dr. Katherine Peters, MD, PhD, FAAN
Walnut Creek, CA, USA, January 31, 2022 – Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough–to–treat cancers, continues to grow its Neuro-Oncology Advisory
Vivacitas Oncology to Present a Poster on AR-67 at the 3rd Annual Glioblastoma Drug Development Summit
Vivacitas will be attending and presenting a poster on its lead asset, AR-67 at the 3rd Annual Glioblastoma Drug Development Summit.